Digital PCR can provide improved BCR-ABL1 detection in chronic myeloid leukemia patients in deep molecular response and sensitivity of standard quantitative methods using EAC assays

Warning

This publication doesn't include Faculty of Sports Studies. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	SMITALOVÁ Dagmar DVORAKOVA D. RÁČIL Zdeněk ROMŽOVÁ Marianna
Year of publication	2021
Type	Article in Periodical
Magazine / Source	Practical Laboratory Medicine
MU Faculty or unit	Central European Institute of Technology
Citation
Web	https://www.sciencedirect.com/science/article/pii/S235255172100010X?via%3Dihub
Doi	http://dx.doi.org/10.1016/j.plabm.2021.e00210
Keywords	Chronic myeloid leukemia; BCR-ABL1 monitoring; GeneXpert BCR-ABL Monitor assay; RT-qPCR; Digital PCR
Description	BCR-ABL1 molecular detection using quantitative PCR (qPCR) methods is the golden standard of chronic myeloid leukemia (CML) monitoring. However, due to variable sensitivity of qPCR assays across laboratories, alternative methods are tested. Digital PCR (dPCR) has been suggested as a robust and reproducible option. Here we present a comparison of droplet dPCR with routinely used reverse-transcription qPCR (RT-qPCR) and automated GeneXpert systems. Detection limit of dPCR was above 3 BCR-ABL1 copies, although due to background amplification the resulting sensitivity was 0.01% BCR-ABL1 (MR4.0). Nevertheless, in comparison with GeneXpert, dPCR categorized more than 50% of the patients into different MR groups, showing a potential for improved BCR-ABL1 detection.
Related projects:	Mutační analýza primitivních buněčných populací u chronické myeloidní leukémie: za hranicí BCR-ABL1 Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VI Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VII